Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (741)	3/2/1998 11:50:00 PM
From: Czechsinthemail	Read Replies (2) \| Respond to of 887

John, Thank you for your follow-up on arachnoiditis. A few questions: Does this data come from DepoTech and perhaps contain various DEPO biases? Do you know if the arachnoiditis is affected by dosage or frequency of use? Is DepoCyt more likely to require Dexamethasone than Methotrexate? And are the side effects accompanying Dexamethasone serious enough that this might negatively affect the view of DepoCyt? It seems like generally good news for DEPO if their primary hurdle will will be establishing efficacy for DepoCyt. Thanks again, Baird

To: Dr. John M. de Castro who wrote (741)	3/3/1998 6:27:00 PM
From: John McCarthy	Read Replies (2) \| Respond to of 887

John - This note is with respect to your note about the side effects of DC. <<DEPO was right>> I know a good number of bright people that have trouble with math. Is it at all possible that folks on the panel cannot undertake the type of Chi Square analysis on the data that you did because of meeting time constraints and/or lack of know-how knowledge? My question is not intended as an type of slanderous comment. The fact is - things did get blown out of proportion. Regards, John McCarthy